Apotheco Pharmacy Group Promotes New Chief Executive Officer Upon David Vucurevich’s Retirement

Apotheco Pharmacy Group Promotes New Chief Executive Officer Upon David Vucurevich’s Retirement




Apotheco Pharmacy Group Promotes New Chief Executive Officer Upon David Vucurevich’s Retirement

NEW YORK & CHICAGO–(BUSINESS WIRE)–Apotheco Pharmacy Group (“Apotheco” or the “Company”), a leading clinically-focused network of specialized pharmacies serving the dermatology market, among other specialties and therapeutic areas, is pleased to announce the promotion of Natasha Hennessy, PharmD. to Chief Executive Officer effective January 1, 2024.

Ms. Hennessy succeeds David Vucurevich, who transitioned to Executive Chairman of the Board following his retirement as CEO.

Mr. Vucurevich said, “Having the opportunity to bring Natasha into Apotheco last July has afforded a seamless transition to her new role as CEO. Throughout her career, Natasha has demonstrated outstanding executive leadership and an unwavering commitment to exceptional results. As I transition into the role of Executive Chairman, I would like congratulate Natasha on her promotion to CEO.”

Ms. Hennessy added, “We are indebted to David for his vision and commitment, which has propelled us to our present position, and we look forward to his continued contributions. I am excited to begin executing on the next stage of Apotheco’s impressive growth and working with the team to build the leading pharmacy network serving the dermatology market and other specialties and therapeutic areas.”

Ms. Hennessy, a pharmacist by training, has served as Executive President at Apotheco since July of 2023 and brings over 15 years of experience in the pharmacy industry with an accomplished track record of driving growth. She most recently served as Chief Operating Officer of Genoa Healthcare, an OptumRx company and the largest provider of pharmacy and medication management services in the behavioral health market with 700+ pharmacies across 47 states. Prior to that, Ms. Hennessy served as General Manager of divvyDOSE, which was acquired by OptumRx in 2020.

Waud Capital Partners (“WCP”), an experienced private equity firm with a track record of successful investments in the pharmacy market, completed a majority investment in Apotheco to support growth in 2019. Since that time, the Company has more than tripled its network of pharmacy locations and added technological advancements to establish itself as a digitally enabled, one-stop shop for dermatology prescriptions.

Chris Graber, Partner at Waud Capital Partners and a member of the Board of Apotheco added, “We are excited to announce Natasha’s promotion to CEO. She has been instrumental to the Company’s success since she joined as Executive President. Natasha brings a wealth of experience in delivering enhanced value for customers, executing technology-enabled growth initiatives, and operating large, multi-site pharmacy networks.”

About Apotheco Pharmacy Group

Apotheco is a leading clinically-focused network of specialized pharmacies serving the dermatology market, among other specialties and therapeutic areas. Through its high-touch model, the Company benefits prescribers, patients, and payors by providing convenience, cost savings, and leading customer service. For additional information on Apotheco, visit www.apothecopharmacy.com.

About Waud Capital Partners

Based in Chicago, Waud Capital Partners is a leading growth-oriented private equity firm with approximately $4.6 billion of assets under management as of December 31, 2022. Waud Capital seeks to partner with experienced management teams to build market-leading companies within two industries: healthcare and software & technology. Since its founding in 1993, Waud Capital has successfully completed more than 450 investments, including platform companies and follow-on opportunities. For additional information on Waud Capital, visit www.waudcapital.com.

Contacts

Rich Myers and Rachel Goun

Profile Advisors

apotheco@profileadvisors.com